S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
This Skill Could Change The Way You Trade! (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
This Skill Could Change The Way You Trade! (Ad)pixel
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
This Skill Could Change The Way You Trade! (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
This Skill Could Change The Way You Trade! (Ad)pixel
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
This Skill Could Change The Way You Trade! (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
This Skill Could Change The Way You Trade! (Ad)pixel
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
This Skill Could Change The Way You Trade! (Ad)pixel
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
This Skill Could Change The Way You Trade! (Ad)pixel
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
NYSE:RDY

Dr. Reddy's Laboratories - RDY Stock Forecast, Price & News

$56.29
+0.17 (+0.30%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$55.64
$56.65
50-Day Range
$49.90
$57.03
52-Week Range
$47.88
$65.86
Volume
255,245 shs
Average Volume
254,668 shs
Market Capitalization
$9.37 billion
P/E Ratio
23.85
Dividend Yield
0.57%
Price Target
$67.00

Dr. Reddy's Laboratories MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
19.0% Upside
$67.00 Price Target
Short Interest
Healthy
0.78% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
1.25mentions of Dr. Reddy
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
11.39%
From $3.16 to $3.52 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.52 out of 5 stars

Medical Sector

149th out of 1,034 stocks

Pharmaceutical Preparations Industry

54th out of 502 stocks

RDY stock logo

About Dr. Reddy's Laboratories (NYSE:RDY) Stock

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Receive RDY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dr. Reddy's Laboratories and its competitors with MarketBeat's FREE daily newsletter.

RDY Stock News Headlines

Dr. Reddys Laboratories (NYSE: RDY)
Dr Reddy's Laboratories Ltd
Dr Reddy's Laboratories Ltd ADR
See More Headlines
Receive RDY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dr. Reddy's Laboratories and its competitors with MarketBeat's FREE daily newsletter.

RDY Company Calendar

Last Earnings
10/29/2021
Today
12/03/2022
Next Earnings (Estimated)
1/27/2023
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
24,795
Year Founded
1984

Price Target and Rating

Average Stock Price Forecast
$67.00
High Stock Price Forecast
$67.00
Low Stock Price Forecast
$67.00
Forecasted Upside/Downside
+19.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$311 million
Pretax Margin
18.88%

Debt

Sales & Book Value

Annual Sales
$2.83 billion
Cash Flow
$3.29 per share
Book Value
$15.22 per share

Miscellaneous

Free Float
163,170,000
Market Cap
$9.37 billion
Optionable
Optionable
Beta
0.42

Social Links


Key Executives

  • Mr. Gunupati Venkateswara Prasad B.E. (Age 62)
    Co-Chairman, MD & Member of Management Council
    Comp: $1.9M
  • Mr. Kallam Satish Reddy B.Tech. (Age 55)
    M.S., Chairman & Member of the Management Council
    Comp: $1.24M
  • Mr. Erez Israeli M.B.A. (Age 54)
    CEO & Member of the Management Council
  • Mr. Parag Agarwal (Age 56)
    CFO & Member of Management Council
  • Mr. Deepak Sapra M.B.A. (Age 47)
    CEO of API & Services & Member of Management Council
  • Mr. Venkata Ramana Motupalli M.B.A. (Age 53)
    MBA, CEO of Branded Markets - India & Emerging Countries and Member of Management Council
  • Ms. Archana Bhaskar B.Sc. (Age 55)
    M.B.A., EVP, Head of Corp. Communications, Chief HR Officer & Member of Management Council
  • Mr. Sanjay Sharma B.Tech. (Age 54)
    Exec. VP, Global Head of Global Manufacturing & Member of Management Council
  • Mr. Marc Kikuchi B.A. (Age 53)
    M.B.A., CEO of North America Generics & Member of Management Council
  • Mr. Patrick Aghanian B.A. (Age 57)
    M.B.A., CEO of European Generics & Member of Management Council













RDY Stock - Frequently Asked Questions

Should I buy or sell Dr. Reddy's Laboratories stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dr. Reddy's Laboratories in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" RDY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RDY, but not buy additional shares or sell existing shares.
View RDY analyst ratings
or view top-rated stocks.

What is Dr. Reddy's Laboratories' stock price forecast for 2023?

2 Wall Street research analysts have issued 12 month price objectives for Dr. Reddy's Laboratories' shares. Their RDY share price forecasts range from $67.00 to $67.00. On average, they anticipate the company's share price to reach $67.00 in the next year. This suggests a possible upside of 19.0% from the stock's current price.
View analysts price targets for RDY
or view top-rated stocks among Wall Street analysts.

How have RDY shares performed in 2022?

Dr. Reddy's Laboratories' stock was trading at $65.41 at the beginning of 2022. Since then, RDY shares have decreased by 13.9% and is now trading at $56.29.
View the best growth stocks for 2022 here
.

Are investors shorting Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories saw a decline in short interest in November. As of November 15th, there was short interest totaling 1,300,000 shares, a decline of 19.8% from the October 31st total of 1,620,000 shares. Based on an average daily volume of 233,700 shares, the days-to-cover ratio is currently 5.6 days.
View Dr. Reddy's Laboratories' Short Interest
.

When is Dr. Reddy's Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, January 27th 2023.
View our RDY earnings forecast
.

How were Dr. Reddy's Laboratories' earnings last quarter?

Dr. Reddy's Laboratories Limited (NYSE:RDY) announced its quarterly earnings data on Friday, October, 29th. The company reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.24. The business earned $777 million during the quarter. Dr. Reddy's Laboratories had a net margin of 13.74% and a trailing twelve-month return on equity of 18.64%.

How often does Dr. Reddy's Laboratories pay dividends? What is the dividend yield for Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories announced an annual dividend on Tuesday, May 24th. Stockholders of record on Monday, July 11th will be paid a dividend of $0.325 per share on Monday, July 11th. This represents a yield of 0.58%. The ex-dividend date of this dividend is Friday, July 8th. This is a boost from the stock's previous annual dividend of $0.29.
Read our dividend analysis for RDY
.

Is Dr. Reddy's Laboratories a good dividend stock?

Dr. Reddy's Laboratories (NYSE:RDY) pays an annual dividend of $0.32 per share and currently has a dividend yield of 0.57%. The company has been increasing its dividend for 3 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 13.56%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RDY will have a dividend payout ratio of 9.09% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RDY.

What is G. V. Prasad's approval rating as Dr. Reddy's Laboratories' CEO?

528 employees have rated Dr. Reddy's Laboratories Chief Executive Officer G. V. Prasad on Glassdoor.com. G. V. Prasad has an approval rating of 96% among the company's employees. This puts G. V. Prasad in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Dr. Reddy's Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dr. Reddy's Laboratories investors own include Siemens Aktiengesellschaft (SIEGY), Tata Motors (TTM), Infosys (INFY), HDFC Bank (HDB), Alibaba Group (BABA), GSK (GSK), Merck & Co., Inc. (MRK), NVIDIA (NVDA) and Pfizer (PFE).

What is Dr. Reddy's Laboratories' stock symbol?

Dr. Reddy's Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "RDY."

Who are Dr. Reddy's Laboratories' major shareholders?

Dr. Reddy's Laboratories' stock is owned by many different institutional and retail investors. Top institutional shareholders include Royal Bank of Canada (1.84%), Renaissance Technologies LLC (1.07%), BlackRock Inc. (1.02%), Vanguard Group Inc. (0.64%), Dimensional Fund Advisors LP (0.50%) and State Street Corp (0.45%).

How do I buy shares of Dr. Reddy's Laboratories?

Shares of RDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dr. Reddy's Laboratories' stock price today?

One share of RDY stock can currently be purchased for approximately $56.29.

How much money does Dr. Reddy's Laboratories make?

Dr. Reddy's Laboratories (NYSE:RDY) has a market capitalization of $9.37 billion and generates $2.83 billion in revenue each year. The company earns $311 million in net income (profit) each year or $2.36 on an earnings per share basis.

How many employees does Dr. Reddy's Laboratories have?

The company employs 24,795 workers across the globe.

How can I contact Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories' mailing address is 8-2-337 ROAD NO.3 BANJARA HILLS, HYDERABAD K7, 500-034. The official website for the company is www.drreddys.com. The company can be reached via phone at 914049002900, via email at amita@drreddys.com, or via fax at 91-40-4900-2999.

This page (NYSE:RDY) was last updated on 12/3/2022 by MarketBeat.com Staff